Literature DB >> 26016572

Exploring calcium oxalate crystallization: a constant composition approach.

Ann M Kolbach-Mandel1, Jack G Kleinman1, Jeffrey A Wesson2,3.   

Abstract

Crystal growth rates have been extensively studied in calcium oxalate monohydrate (COM) crystallization, because COM crystals are the principal component in most kidney stones. Constant composition methods are useful for studying growth rates, but fail to differentiate concurrent nucleation and aggregation events. A constant composition method coupled with particle size determinations that addresses this deficiency was previously published for a calcium phosphate system, and this method was extended to COM crystallization in this report. A seeded constant composition experiment was combined with particle size determination and a separate near-equilibrium aggregation experiment to separate effects of growth rate, nucleation, and aggregation in COM crystal formation and to test the effects of various inhibitors relevant to stone formation. With no inhibitors present, apparent COM growth rates were heavily influenced by secondary nucleation at low seed crystal additions, but growth-related aggregation increased at higher seed crystal densities. Among small molecule inhibitors, citrate demonstrated growth rate inhibition but enhanced growth-related aggregation, while magnesium did not affect COM crystallization. Polyanions (polyaspartate, polyglutamate, or osteopontin) showed strong growth rate inhibition, but large differences in nucleation and aggregation were observed. Polycations (polyarginine) did not affect COM crystal growth or aggregation. Mixtures of polyanions and polycations produced a complicated set of growth rate, nucleation, and aggregation behaviors. These experiments demonstrated the power of combining particle size determinations with constant composition experiments to fully characterize COM crystallization and to obtain detailed knowledge of inhibitor properties that will be critical to understanding kidney stone formation.

Entities:  

Keywords:  Calcium oxalate; Constant composition; Crystal aggregation; Crystal inhibitors; Nephrolithiasis; Osteopontin

Mesh:

Substances:

Year:  2015        PMID: 26016572      PMCID: PMC4573792          DOI: 10.1007/s00240-015-0781-5

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  35 in total

1.  The effect of avian uterine fluid on the growth behavior of calcite crystals.

Authors:  J M Dominguez-Vera; J Gautron; J M Garcia-Ruiz; Y Nys
Journal:  Poult Sci       Date:  2000-06       Impact factor: 3.352

2.  Self-assembly of model DNA-binding peptide amphiphiles.

Authors:  Ronit Bitton; Judith Schmidt; Markus Biesalski; Raymond Tu; Matthew Tirrell; Havazelet Bianco-Peled
Journal:  Langmuir       Date:  2005-12-06       Impact factor: 3.882

3.  Mineralization kinetics: a constant composition approach.

Authors:  M B Tomson; G H Nancollas
Journal:  Science       Date:  1978-06-02       Impact factor: 47.728

4.  The effect of gallium on seeded hydroxyapatite growth.

Authors:  R Donnelly; A Boskey
Journal:  Calcif Tissue Int       Date:  1989-02       Impact factor: 4.333

5.  Effect of two new polysaccharides on growth, agglomeration and zeta potential of calcium phosphate crystals.

Authors:  E R Boevé; L C Cao; G Deng; W C De Bruijn; F H Schröder
Journal:  J Urol       Date:  1996-01       Impact factor: 7.450

6.  The mineralization inhibitory potential of urines: a constant composition approach.

Authors:  A C Lanzalaco; M E Sheehan; D J White; G H Nancollas
Journal:  J Urol       Date:  1982-10       Impact factor: 7.450

7.  Molecular modulation of calcium oxalate crystallization by osteopontin and citrate.

Authors:  S R Qiu; A Wierzbicki; C A Orme; A M Cody; J R Hoyer; G H Nancollas; S Zepeda; J J De Yoreo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-06       Impact factor: 11.205

8.  Inhibitory activity of whole urine: a comparison of urines from stone formers and healthy subjects.

Authors:  R L Ryall; C M Hibberd; B C Mazzachi; V R Marshall
Journal:  Clin Chim Acta       Date:  1986-01-15       Impact factor: 3.786

9.  Modulation of calcium oxalate dihydrate growth by selective crystal-face binding of phosphorylated osteopontin and polyaspartate peptide showing occlusion by sectoral (compositional) zoning.

Authors:  Yung-Ching Chien; David L Masica; Jeffrey J Gray; Sarah Nguyen; Hojatollah Vali; Marc D McKee
Journal:  J Biol Chem       Date:  2009-07-06       Impact factor: 5.157

10.  Zeta potential measurement and particle size analysis for a better understanding of urinary inhibitors of calcium oxalate crystallization.

Authors:  L C Cao; G Deng; E R Boevé; W C de Bruijn; R de Water; C F Verkoelen; J C Romijn; F H Schröder
Journal:  Scanning Microsc       Date:  1996
View more
  5 in total

1.  Stone former urine proteome demonstrates a cationic shift in protein distribution compared to normal.

Authors:  Ann M Kolbach-Mandel; Neil S Mandel; Brian R Hoffmann; Jack G Kleinman; Jeffrey A Wesson
Journal:  Urolithiasis       Date:  2017-03-17       Impact factor: 3.436

Review 2.  The role of macromolecules in the formation of kidney stones.

Authors:  Jeffrey D Rimer; Ann M Kolbach-Mandel; Michael D Ward; Jeffrey A Wesson
Journal:  Urolithiasis       Date:  2016-12-02       Impact factor: 3.436

Review 3.  Liquid-Liquid Phase Separation in Nucleation Process of Biomineralization.

Authors:  Da Qin; Zhen He; Peng Li; Shutian Zhang
Journal:  Front Chem       Date:  2022-02-04       Impact factor: 5.221

4.  Roles of heat-shock protein 90 and its four domains (N, LR, M and C) in calcium oxalate stone-forming processes.

Authors:  Sunisa Yoodee; Paleerath Peerapen; Sirikanya Plumworasawat; Visith Thongboonkerd
Journal:  Cell Mol Life Sci       Date:  2022-07-28       Impact factor: 9.207

5.  Metabolic and Network Pharmacological Analyses of the Therapeutic Effect of Grona styracifolia on Calcium Oxalate-Induced Renal Injury.

Authors:  Wei Chen; Yachen Si; Jin Cheng; Jiarong Ding; Hongxia Zhao; Wenrui Liu; Qishan Lin; Jiebin Hou; Zhiyong Guo
Journal:  Front Pharmacol       Date:  2021-06-25       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.